Dupilumab Gains Pediatric CSU Approval
Targets type 2 inflammation in a population with limited treatment options
-
By
-
Kathryn Wighton
-
April 24, 2026
-
Clinical Scorecard: Dupilumab Gains Pediatric CSU Approval
At a Glance
| Category | Detail |
|---|
| Condition | Chronic Spontaneous Urticaria (CSU) |
| Key Mechanisms | Inhibition of interleukin-4 and interleukin-13 signaling pathways |
| Target Population | Pediatric patients aged 2 to 11 years |
| Care Setting | Clinical settings or at home following caregiver training |
Key Highlights
- Dupilumab approved for pediatric patients with CSU unresponsive to antihistamines
- Phase 3 trials showed reduced itch severity and improved disease control
- First biologic therapy approved in the US for young children with CSU
- Safety profile consistent with previous indications, no new safety concerns
- Injection site reactions most common adverse event reported
Guideline-Based Recommendations
Diagnosis
- Diagnosis of CSU based on clinical history and symptomatology
Management
- Use of dupilumab in patients with inadequate response to antihistamines
Monitoring & Follow-up
- Monitor for injection site reactions and overall treatment response
Risks
- Potential for injection site reactions; no new safety concerns identified
Patient & Prescribing Data
Pediatric patients aged 2 to 11 years with CSU
Dosing based on age and weight; administered via subcutaneous injection
Clinical Best Practices
- Consider dupilumab for patients with CSU who are symptomatic despite antihistamine therapy
- Educate caregivers on administration techniques for home use
Related Resources & Content
